Cambiar Investors LLC Sells 3,634 Shares of Novartis AG (NYSE:NVS)

Cambiar Investors LLC decreased its stake in Novartis AG (NYSE:NVS) by 2.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 121,975 shares of the company’s stock after selling 3,634 shares during the period. Cambiar Investors LLC’s holdings in Novartis were worth $11,869,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Legacy Investment Solutions LLC bought a new position in shares of Novartis in the 3rd quarter worth $28,000. Union Bancaire Privee UBP SA bought a new position in shares of Novartis in the 4th quarter worth $27,000. Fortitude Family Office LLC increased its holdings in shares of Novartis by 503.8% in the 3rd quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock worth $37,000 after buying an additional 267 shares during the last quarter. Brooklyn Investment Group bought a new position in shares of Novartis in the 4th quarter worth $55,000. Finally, Beaird Harris Wealth Management LLC increased its holdings in shares of Novartis by 280.5% in the 3rd quarter. Beaird Harris Wealth Management LLC now owns 704 shares of the company’s stock worth $81,000 after buying an additional 519 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Novartis Trading Up 0.5 %

Shares of NVS opened at $106.81 on Tuesday. The stock has a market capitalization of $218.31 billion, a P/E ratio of 18.16, a PEG ratio of 1.70 and a beta of 0.58. The company has a quick ratio of 0.90, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The firm has a fifty day simple moving average of $100.32 and a two-hundred day simple moving average of $108.39. Novartis AG has a twelve month low of $92.35 and a twelve month high of $120.92.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. On average, research analysts anticipate that Novartis AG will post 8.42 EPS for the current year.

Analysts Set New Price Targets

NVS has been the topic of several recent research reports. StockNews.com raised shares of Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday. Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft raised shares of Novartis from a “hold” rating to a “buy” rating in a report on Tuesday, February 4th. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Finally, BMO Capital Markets increased their target price on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.